Measuring the end-of-life premium in cancer using individual ex ante willingness to pay
Crossref DOI link: https://doi.org/10.1007/s10198-017-0922-6
Published Online: 2017-08-12
Published Print: 2018-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Olofsson, S. http://orcid.org/0000-0003-2609-2065
Gerdtham, U.-G.
Hultkrantz, L.
Persson, U.
Funding for this research was provided by:
Janssen Pharmaceutica NV
License valid from 2017-08-12